Potent and orally active ET A selective antagonists with 5,7-diarylcyclopenteno[1,2- b]pyridine-6-carboxylic acid structures

Abstract

The synthesis and structure–activity relationships of a series of 5,7-diarylcyclopenteno[1,2- b]pyridine-6-carboxylic acids are described. Our efforts have been focused on modification of the aryl ring at the 5-position and the alkyl substituent at the 2-position of the bottom 4-methoxyphenyl ring in an effort to develop orally available ET A selective antagonists with safer profiles in terms of the P-450 enzyme inhibitory activity. Incorporation of a hydroxymethyl group as an alkyl substituent in methylenedioxyphenyl and 6-dihydrobenzofuran derivatives led to the identification of orally bioavailable ET A selective antagonists 1f and 7f. These compounds also showed not only excellent binding affinity (IC 50 < 0.10 nM, more than 800-fold selectivity for the ET A receptor over the ET B receptor) but also sufficient oral bioavailability, 48% and 56%, respectively, in rats. Furthermore, these compounds did not exhibit either competitive or mechanism-based inhibition of human cytochrome P450 enzymes.